To evaluate the specificity of EDN3 and NLGN4X to BPDCN, we analyzed their expression in 12 BPDCN vs. 35 T-Cell Acute Lymphoblastic Leukemia (T-ALL) and vs. 65 AML cases, available in silico (GSE89565). Here, NLGN4X is linked to acute myeloid leukemia.